Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $119

Benzinga · 07/08 16:32
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $126 to $119.